Osaic Holdings
ARQT icon

Osaic Holdings’s Arcutis Biotherapeutics ARQT Stock Holding History

Osaic Holdings’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Buy
6,076
+623
+11% +$14.5K ﹤0.01% 4597
2026
Q1 		$128K Sell
5,453
-45
-0.8% -$1.15K ﹤0.01% 4494
2025
Q4 		$160K Buy
5,498
+75
+1% +$1.92K ﹤0.01% 4327
2025
Q3 		$87.1K Sell
5,423
-568
-9% -$8.96K ﹤0.01% 4909
2025
Q2 		$84K Sell
5,991
-616
-9% -$8.64K ﹤0.01% 4650
2025
Q1 		$103K Sell
6,607
-3,568
-35% -$50.3K ﹤0.01% 4140
2024
Q4 		$142K Buy
10,175
+7,747
+319% +$84.9K ﹤0.01% 3905
2024
Q3 		$22.6K Buy
2,428
+138
+6% +$1.36K ﹤0.01% 5310
2024
Q2 		$21.3K Sell
2,290
-26,336
-92% -$238K ﹤0.01% 5301
2024
Q1 		$284K Buy
28,626
+7,358
+35% +$54.9K ﹤0.01% 3385
2023
Q4 		$68.7K Buy
21,268
+19,142
+900% +$52K ﹤0.01% 4686
2023
Q3 		$11.3K Buy
2,126
+1,084
+104% +$9.22K ﹤0.01% 5855
2023
Q2 		$9.96K Buy
1,042
+400
+62% +$4.44K ﹤0.01% 5964
2023
Q1 		$7.2K Buy
642
+100
+18% +$1.45K ﹤0.01% 6161
2022
Q4 		$8K Buy
542
+85
+19% +$1.49K ﹤0.01% 6050
2022
Q3 		$9K Hold
457
– – ﹤0.01% 6054
2022
Q2 		$11K Buy
457
+57
+14% +$1.17K ﹤0.01% 6002
2022
Q1 		$8K Hold
400
– – ﹤0.01% 6252
2021
Q4 		$8K Sell
400
-330
-45% -$6.57K ﹤0.01% 6386
2021
Q3 		$18K Sell
730
-2,034
-74% -$46.4K ﹤0.01% 5838
2021
Q2 		$75K Buy
2,764
+2,058
+292% +$58K ﹤0.01% 4726
2021
Q1 		$21K Sell
706
-11,255
-94% -$351K ﹤0.01% 5425
2020
Q4 		$336K Buy
11,961
+11,561
+2,890% +$283K ﹤0.01% 3016
2020
Q3 		$12K Hold
400
– – ﹤0.01% 5165
2020
Q2 		$12K Hold
400
– – ﹤0.01% 5080
2020
Q1 		$12K Buy
+400
New +$10.7K ﹤0.01% 4893

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Osaic Holdings's ARQT Position: Q2 2026 in Review

Osaic Holdings increased its Arcutis Biotherapeutics (ARQT) stake by 11% in Q2 2026, buying an estimated $14.5K and bringing the position to 6,076 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #4597.

Osaic Holdings first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $336K in Q4 2020. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Osaic Holdings held 6,076 shares of Arcutis Biotherapeutics worth $159K as of Q2 2026.
  • Osaic Holdings bought 623 Arcutis Biotherapeutics shares in Q2 2026, an estimated $14.5K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #4597 holding.
  • Osaic Holdings first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Arcutis Biotherapeutics position peaked at $336K in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.